<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758248</url>
  </required_header>
  <id_info>
    <org_study_id>Gene Polymorphism</org_study_id>
    <nct_id>NCT03758248</nct_id>
  </id_info>
  <brief_title>The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI</brief_title>
  <official_title>The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in
      patients undergoing percutaneous coronary intervention (PCI). However, despite intensified
      antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent
      occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some
      patients develop bleeding event because of the improper dosage and covariation. This
      observational study is designed for clarifying the Influence of gene gene polymorphism and
      clinical outcomes in patients undergoing PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing PCI who received dual-antiplatelet therapy with both aspirin (100mg) and
      thienopyridines in standard dosage were enrolled. Investigators examined plasma biomarkers
      for platelet activation and DNA in those patients. Then analyzed the CYP2C19 genetic
      polymorphism to examine the influence of this genetic variation on the several biomarkers for
      platelet activation and bleeding event.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>10000 patients with treatment-related major bleeding events as assessed by BARC Bleeding Definition</measure>
    <time_frame>up to 12months</time_frame>
    <description>The major bleeding event was a composite endpoint, defined according to the Bleeding Academic Research Consortium(BARC) criteria, which was used widely in this field. BARC bleeding was defined as follows: BARC type 1, any bleeding that is not actionable; type 2, any overt, actionable sign of bleeding; type 3a, overt bleeding with a haemoglobin drop of 3-5 g/dL or any transfusion; type 3b, overt bleeding with a haemoglobin drop &gt;5 g/dL, requiring vasopressors, surgical intervention, or due to cardiac tamponade; type 3c, any intracranial or intraocular bleeding;and finally type 5, any bleeding resulting in death(Type 4 was coronary artery bypass graft, which was excluded). Investigator will get all the information through regular return visit and telephone follow-up at 1 month,6 month, 1year after discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>A composite of death, myocardial infarction, stroke, stent thrombosis, and ischemia-driven revascularization at 1，6，12 month after discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Antiplatelet Therapy</condition>
  <condition>CYP2C19 Polymorphism</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CYP2C19</intervention_name>
    <description>The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19*17 carriers) or higher (CYP2C19*2 carriers) risk of major adverse cardiovascular events.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      gene alteration is measured by using whole blood in patients undergoing PCI.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PCI Patients in Anzhen hospital from August 2018-August 2019
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients undergoing PCI

          2. More than 18 years old

          3. Treated with aspirin and thienopyridine（clopidogrel or ticagrelor）

        Exclusion Criteria:

        Inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <phone>8613901330652</phone>
    <email>azzyj12@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou, MD, PhD</last_name>
      <phone>8613901330652</phone>
      <email>azzyj12@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yujing Cheng, MD</last_name>
      <phone>8613426481193</phone>
      <email>13426481193@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yujie Zhou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>May 5, 2019</last_update_submitted>
  <last_update_submitted_qc>May 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Genotype-guided therapy</keyword>
  <keyword>CYP2C19 Polymorphism</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

